Filing Flows › Organogenesis Holdings (ORGO) › R&D spending
Organogenesis Holdings (ORGO) R&D spending by quarter
Organogenesis Holdings' R&D spending was $8.0M in Q3 2026 (third quarter 2026), -56% from Q2 2026. Over the last 7 quarters it ranged from $8.0M (Q3 2026) to $18.3M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $8.0M | -56% | -40% |
| Q2 2026 | $18.3M | +21% | +76% |
| Q1 2026 | $15.2M | +47% | +42% |
| Q4 2025 | $10.3M | -22% | — |
| Q3 2025 | $13.2M | +27% | — |
| Q2 2025 | $10.4M | -2% | — |
| Q1 2025 | $10.6M | — | — |
Q3 2026 at a glance
Organogenesis Holdings, Q3 2026: revenue $45.5M (-70% year over year), operating margin -64.9%, net loss $29.6M, operating cash flow −$18.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Organogenesis Holdings' R&D spending?
Organogenesis Holdings' R&D spending was $8.0M in Q3 2026 (third quarter 2026), -56% from Q2 2026.
How has Organogenesis Holdings' R&D spending changed?
Over the last 7 quarters it ranged from $8.0M (Q3 2026) to $18.3M (Q2 2026).
Q3 2026 results → · How Organogenesis Holdings makes money →